Paula Carolina de Souza

Dr. Paula Carolina de Souza

ICB-IV USP
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPatricia Bento Da Silva
Patricia Bento Da Silva
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
Giovana CalixtoGiovana Calixto
Giovana Calixto
ELErica De O. Lopes
Erica De O. Lopes
RFRegina C. G. Frem
Regina C. G. Frem
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Tuberculosis (TB) is an infectious disease caused mainly by the bacillus Mycobacterium tuberculosis (Mtb), presenting 9.5 million new cases and 1.5 million deaths in 2014. The aim of this study was to evaluate a nanostructured lipid system (NLS) composed of 10% phase oil (cholesterol), 10% surfactant (soy phosphatidylcholine, sodium oleate), and Eumulgin® HRE 40 ([castor oil polyoxyl-40-hydrogenated] in a proportion of 3:6:8), and an 80% aqueous phase (phosphate buffer pH = 7.4) as a tactic to enhance the in vitro anti-Mtb activity of the copper(II) complexes [CuCl2(INH)2]·H2O (1), [Cu(NCS)2(INH)2]·5H2O (2) and [Cu(NCO)2(INH)2]·4H2O (3). The Cu(II) complex-loaded NLS displayed sizes ranging from 169.5 ± 0.7095 to 211.1 ± 0.8963 nm, polydispersity index (PDI) varying from 0.135 ± 0.0130 to 0.236 ± 0.00100, and zeta potential ranging from −0.00690 ± 0.0896 to −8.43 ± 1.63 mV. Rheological analysis showed that the formulations behave as non-Newtonian fluids of the pseudoplastic and viscoelastic type. Antimycobacterial activities of the free complexes and NLS-loaded complexes against Mtb H37Rv ATCC 27294 were evaluated by the REMA methodology, and the selectivity index (SI) was calculated using the cytotoxicity index (IC50) against Vero (ATCC® CCL-81), J774A.1 (ATCC® TIB-67), and MRC-5 (ATCC® CCL-171) cell lines. The data suggest that the incorporation of the complexes into NLS improved the inhibitory action against Mtb by 52-, 27-, and 4.7-fold and the SI values by 173-, 43-, and 7-fold for the compounds 1, 2 and 3, respectively. The incorporation of the complexes 1, 2 and 3 into the NLS also resulted in a significant decrease of toxicity towards an alternative model (Artemia salina L.). These findings suggest that the NLS may be considered as a platform for incorporation of metallic complexes aimed at the treatment of TB.

26 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DCDébora Leite Campos
Débora Leite Campos
FDFernanda Manaia Demarqui
Fernanda Manaia Demarqui
MSMariana Cristina Solcia
Mariana Cristina Solcia
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
PMPedro Ivo da Silva Maia
Pedro Ivo da Silva Maia
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.

18 January 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
NPNayla De Souza Pitangui
Nayla De Souza Pitangui
JSJunya Singulani
Junya Singulani
JSJANAINA DE CÁSSIA ORLANDI SARDI
JANAINA DE CÁSSIA ORLANDI SARDI
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
GRGabriela Rodríguez-Arellanes
Gabriela Rodríguez-Arellanes
AFAna Marisa Fusco-Almeida
Ana Marisa Fusco-Almeida
Histoplasma capsulatum affects healthy and immunocompromised individuals, sometimes causing a severe disease. This fungus has two morphotypes, the mycelial (infective) and the yeast (parasitic) phases. MicroRNAs (miRNAs) are small RNAs involved in the regulation of several cellular processes, and their differential expression has been associated with many disease states. To investigate miRNA expression in host cells during H. capsulatum infection, we studied the changes in the miRNA profiles of differentiated human macrophages infected with yeasts from two fungal strains with different virulence, EH-315 (high virulence) and 60I (low virulence) grown in planktonic cultures, and EH-315 grown in biofilm form. MiRNA profiles were evaluated by means of reverse transcription-quantitative polymerase chain reaction using a commercial human miRNome panel. The target genes of the differentially expressed miRNAs and their corresponding signaling pathways were predicted using bioinformatics analyses. Here, we confirmed biofilm structures were present in the EH-315 culture whose conditions facilitated producing insoluble exopolysaccharide and intracellular polysaccharides. In infected macrophages, bioinformatics analyses revealed especially increased (hsa-miR-99b-3p) or decreased (hsa-miR-342-3p) miRNAs expression levels in response to infection with biofilms or both growth forms of H. capsulatum yeasts, respectively. The results of miRNAs suggested that infection by H. capsulatum can affect important biological pathways of the host cell, targeting two genes: one encoding a protein that is important in the cortical cytoskeleton; the other, a protein involved in the formation of stress granules. Expressed miRNAs in the host’s response could be proposed as new therapeutic and/or diagnostic tools for histoplasmosis.

1 November 2017
Verified
Conference Paper
Open access
GFGuilherme Fernandes
Guilherme Fernandes
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
Tuberculosis (TB) is an infectious disease caused by the bacterium, Mycobacterium tuberculosis (Mtb). The last surveys conducted by the World Health Organization (WHO) have described TB as the infectious disease responsible for the highest number of deaths worldwide. Furthermore, an increasing number of multidrug-resistant (MDR) and extensively-drug resistant (XDR) strains have complicated the scenario. In this regard, various N-oxide derivatives, such as furoxan, benzofuroxan, and quinoxaline 1,4-di-N-oxide, have been previously described as promising scaffolds with a potential to be explored as novel antitubercular drugs. Herein, 22 new N-oxide-containing compounds were synthesized followed by in vitro evaluation of their antitubercular potential against Mtb. Moreover, their safety and primary mechanism of action were also explored. The compounds demonstrated MIC90 values ranging from 0.40 to 62 μM. Among the different heterocyclic compounds containing N-oxide, the benzofuroxan derivative 8 was found to be the most promising compound, with MIC90 values of 1.10 and 6.62 μM against active and non-replicating Mtb, respectively. Cytotoxicity tests using MRC–5 cell line demonstrated an IC50 value of 519.2 μM. Compound 8 was also active against monoresistant strains. Microarray-based initial studies on the mechanism of action revealed an upregulation of a number of transcripts encoding proteins belonging to both small and large subunits of the ribosome, suggesting that compound 8 blocked the process of translation. Altogether, these results indicated benzofuroxan derivative 8 to be a promising lead compound for the development of a novel chemical class of antitubercular drugs.